Cancer Testing With Synthetic Biomarkers

Synthetic Biomarkers for Early Cancer Detection

Synthetic Biomarkers are Emerging technology towards development of early cancer detection. This Technology includes administration of exogenous drugs to assess biological function in vivo has a long clinical history.

Synthetic biomarkers are kind of sensors and small-molecule probes activated by certain enzymes in the tumor or its microenvironment to amplify molecular mechanisms of the tumors, thus indicating at very advance stages of a tumor activity in the body. This is achieved by bringing down the required limit of

This helps the doctors to identify the diseases such as cancers at a very early stage and treat it accordingly.

Synthetic biomarkers of protease activation include peptide substrates bound to the surface of a carrier substance that releases a reporter chemical agent for detection in blood or urine after being attached to a tumor protease. This results in molecular signal amplification which them gets detected by the scanners and other tests. Most commonly detected cancers using this process are Liver Cancers, Prostate cancers and Breast Cancers.

As the diagnostic technology which as of now is mostly on developmental phase, moves towards actual human testing, the components that are used for synthetic biomarkers are under clinical testing for a larger safety records for larger range of tests. This is currently limited to select cancers only.

Other New Technology for Cancer Diagnostics –